Compare Stocks: REGN, LLY, NVO, and SNY

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
LLY Eli Lilly and Company	$1,433.34 -0.3%	$1,236.58	$850.51 ▼ $1,460.00	$1.35T	0.4	3.07 million shs	2.40 million shs
NVO Novo Nordisk A/S	$40.66 -1.0%	$40.20	$35.12 ▼ $64.16	$183.47B	0.7	11.30 million shs	15.75 million shs
REGN Regeneron Pharmaceuticals	$951.19 -0.9%	$813.93	$591.52 ▼ $991.73	$99.25B	0.1	963,399 shs	1.21 million shs
SNY Sanofi	$48.46 +0.1%	$42.60	$39.07 ▼ $52.68	$117.41B	0.31	4.79 million shs	2.36 million shs

Forget Nvidia, Meta, and Google. Here's The New Magnificent Seven.

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
LLY Eli Lilly and Company	-0.29%	+4.71%	+22.82%	+21.24%	+40.76%
NVO Novo Nordisk A/S	-1.13%	+0.93%	+6.91%	-11.43%	-19.09%
REGN Regeneron Pharmaceuticals	-0.86%	+5.35%	+26.30%	+18.38%	+39.53%
SNY Sanofi	+0.06%	+3.30%	+23.88%	+10.84%	-6.66%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
LLY Eli Lilly and Company	$1,433.34 -0.3%	$1,236.58	$850.51 ▼ $1,460.00	$1.35T	0.4	3.07 million shs	2.40 million shs
NVO Novo Nordisk A/S	$40.66 -1.0%	$40.20	$35.12 ▼ $64.16	$183.47B	0.7	11.30 million shs	15.75 million shs
REGN Regeneron Pharmaceuticals	$951.19 -0.9%	$813.93	$591.52 ▼ $991.73	$99.25B	0.1	963,399 shs	1.21 million shs
SNY Sanofi	$48.46 +0.1%	$42.60	$39.07 ▼ $52.68	$117.41B	0.31	4.79 million shs	2.36 million shs

Forget Nvidia, Meta, and Google. Here's The New Magnificent Seven.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
LLY Eli Lilly and Company	-0.29%	+4.71%	+22.82%	+21.24%	+40.76%
NVO Novo Nordisk A/S	-1.13%	+0.93%	+6.91%	-11.43%	-19.09%
REGN Regeneron Pharmaceuticals	-0.86%	+5.35%	+26.30%	+18.38%	+39.53%
SNY Sanofi	+0.06%	+3.30%	+23.88%	+10.84%	-6.66%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
LLY Eli Lilly and Company	2.83	Moderate Buy	$1,416.64	-1.17% Downside
NVO Novo Nordisk A/S	2.00	Hold	$59.44	46.17% Upside
REGN Regeneron Pharmaceuticals	2.74	Moderate Buy	$898.97	-5.49% Downside
SNY Sanofi	2.48	Hold	$53.00	9.37% Upside

Current Analyst Ratings Breakdown

Latest REGN, LLY, NVO, and SNY Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
11/12/2026	LLY Eli Lilly and Company	China Merchants Securities Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Buy ➝ Hold
11/9/2026	SNY Sanofi	BNP Paribas Exane Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Neutral ➝ Outperform	$57.00
11/9/2026	LLY Eli Lilly and Company	Jefferies Financial Group Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Buy	$1,610.00 ➝ $1,700.00
11/2/2026	REGN Regeneron Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Hold (C) ➝ Hold (C+)
11/2/2026	SNY Sanofi	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Sell (D+) ➝ Hold (C-)
11/2/2026	LLY Eli Lilly and Company	Cantor Fitzgerald Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Overweight	$1,440.00 ➝ $1,600.00
11/2/2026	REGN Regeneron Pharmaceuticals	Leerink Partners Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Market Perform	$835.00 ➝ $997.00
11/2/2026	REGN Regeneron Pharmaceuticals	Sanford C. Bernstein Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Market Perform	$756.00 ➝ $812.00
11/2/2026	REGN Regeneron Pharmaceuticals	Morgan Stanley Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Equal Weight	$779.00 ➝ $855.00
11/2/2026	REGN Regeneron Pharmaceuticals	Truist Financial Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Buy	$780.00 ➝ $982.00
11/2/2026	REGN Regeneron Pharmaceuticals	Royal Bank Of Canada Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Sector Perform	$810.00 ➝ $913.00

(Data available from 11/13/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
LLY Eli Lilly and Company	$65.18B	20.69	$25.07 per share	57.18	$42.81 per share	33.48
NVO Novo Nordisk A/S	$46.80B	3.88	$4.64 per share	8.77	$7.51 per share	5.41
REGN Regeneron Pharmaceuticals	$14.34B	6.86	$41.61 per share	22.86	$323.82 per share	2.94
SNY Sanofi	$49.35B	2.38	$7.07 per share	6.85	$34.77 per share	1.39

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
LLY Eli Lilly and Company	$20.64B	$30.81	46.52	28.27	1.72	31.90%	86.76%	22.03%	N/A
NVO Novo Nordisk A/S	$15.51B	$3.97	10.56	11.79	1.41	33.99%	53.52%	19.49%	N/A
REGN Regeneron Pharmaceuticals	$4.50B	$45.29	21.00	15.15	1.27	28.51%	16.01%	12.22%	1/28/2027 (Estimated)
SNY Sanofi	$8.84B	$2.02	23.99	8.88	1.33	8.70%	15.16%	8.48%	N/A

Latest REGN, LLY, NVO, and SNY Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
10/30/2026	Q3 2026	REGN Regeneron Pharmaceuticals	$16.51	$20.07	+$3.56	$18.45	$4.58 billion	$5.12 billion
10/30/2026	Q3 2026	SNY Sanofi	$1.56	$2.04	+$0.48	$1.43	$14.30 billion	$17.25 billion
10/29/2026	Q3 2026	LLY Eli Lilly and Company	$5.71	$7.48	+$1.77	$7.22	$22.58 billion	$24.40 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
LLY Eli Lilly and Company	$6.92	0.48%	+15.18%	22.46%	11 Years
NVO Novo Nordisk A/S	$0.82	2.02%	+21.74%	20.65%	N/A
REGN Regeneron Pharmaceuticals	$3.76	0.40%	N/A	8.30%	N/A
SNY Sanofi	$1.76	3.63%	+6.46%	87.13%	N/A

Latest REGN, LLY, NVO, and SNY Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
10/26/2026	LLY Eli Lilly and Company	quarterly	$1.73	0.48%	11/13/2026	11/13/2026	12/10/2026
10/30/2026	REGN Regeneron Pharmaceuticals	quarterly	$0.94	0.41%	11/20/2026	11/20/2026	12/3/2026

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
LLY Eli Lilly and Company	1.17	1.39	1.00
NVO Novo Nordisk A/S	0.54	0.84	0.64
REGN Regeneron Pharmaceuticals	0.06	3.35	2.89
SNY Sanofi	0.20	1.12	0.27

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
LLY Eli Lilly and Company	82.53%
NVO Novo Nordisk A/S	11.54%
REGN Regeneron Pharmaceuticals	83.31%
SNY Sanofi	14.03%

Insider Ownership

Company	Insider Ownership
LLY Eli Lilly and Company	0.14%
NVO Novo Nordisk A/S	0.07%
REGN Regeneron Pharmaceuticals	6.97%
SNY Sanofi	1.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
LLY Eli Lilly and Company	50,000	940.74 million	939.43 million	Optionable
NVO Novo Nordisk A/S	69,505	4.47 billion	4.46 billion	Optionable
REGN Regeneron Pharmaceuticals	15,410	103.45 million	96.24 million	Optionable
SNY Sanofi	74,846	2.42 billion	2.40 billion	Optionable

REGN, LLY, NVO, and SNY Headlines

Recent News About These Companies

1,029,860 Sanofi $SNY Shares Sold by Fisher Asset Management LLC

1 hour ago | marketbeat.com

Sanofi (NASDAQ:SNY) Stock Has Average Target Price of $53.00 According to Brokerages

November 11 at 4:13 AM | marketbeat.com

Sanofi (NASDAQ:SNY) Upgraded at Wall Street Zen

November 10 at 2:31 AM | americanbankingnews.com

BNP Paribas Exane Upgrades Sanofi (SAN:FP) (SNY) to Outperform

November 9, 2026 | streetinsider.com

Sanofi (NASDAQ:SNY) Stock Rating Raised to "Buy" at Wall Street Zen

November 7, 2026 | marketbeat.com

Sanofi $SNY Stock Acquired by Pzena Investment Management LLC

November 6, 2026 | marketbeat.com

Sanofi (NASDAQ:SNY) Stock Crosses Above 200-Day Moving Average - Here's What Happened

November 3, 2026 | marketbeat.com

Sanofi 2026 Q3 - Results - Earnings Call Presentation

November 3, 2026 | seekingalpha.com

Sanofi (SNY) Q3 2026 Earnings Call Transcript

November 2, 2026 | finance.yahoo.com

Walled Lake Planning & Wealth Management LLC Acquires 45,885 Shares of Sanofi $SNY

November 2, 2026 | marketbeat.com

Sanofi (NASDAQ:SNY) Issues Quarterly Earnings Results, Beats Expectations By $0.48 EPS

October 31, 2026 | marketbeat.com

Sanofi (NASDAQ:SNY) Sees Strong Trading Volume - Should You Buy?

October 30, 2026 | marketbeat.com

Sanofi Q3 Earnings Call Highlights

October 30, 2026 | marketbeat.com

Regeneron Surges 12% as Sanofi Dupixent Windfall and Eylea HD Power Earnings Beat; Moderna Slides 2%, Merck Edges Higher, Pfizer Ticks Up

October 30, 2026 | 247wallst.com

Sanofi Q3 Earnings & Sales Beat, 2026 View Up, Shares Rise

October 30, 2026 | zacks.com

Sanofi Q3 Profit Climbs On Dupixent Growth; Raises FY26 Guidance; Stock Up

October 30, 2026 | rttnews.com

Sanofi Tops Q3 2026 Expectations as Dupixent Sales Reach $6.36 Billion

October 30, 2026 | 247wallst.com

Sanofi lifts profit outlook on strong Dupixent sales

October 30, 2026 | seekingalpha.com

Sanofi CEO Sets Sights on Deals to Drive Turnaround

October 30, 2026 | wsj.com

Leo Wealth LLC Purchases 25,063 Shares of Sanofi $SNY

October 27, 2026 | marketbeat.com

Sanofi $SNY Stock: Quadrant Capital Group LLC Trims Position

October 27, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

REGN, LLY, NVO, and SNY Company Descriptions

Eli Lilly and Company NYSE:LLY

$1,433.34 -3.95 (-0.27%)

Closing price 11/12/2026 03:59 PM Eastern

Extended Trading

$1,433.57 +0.23 (+0.02%)

As of 06:15 AM Eastern

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; and Chugai Pharmaceutical Co., Ltd. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Novo Nordisk A/S NYSE:NVO

$40.66 -0.43 (-1.04%)

Closing price 11/12/2026 03:59 PM Eastern

Extended Trading

$40.73 +0.07 (+0.16%)

As of 06:16 AM Eastern

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with Aspen Pharmaceuticals to produce insulin products; and with Korro Bio, Inc. for the discovery and development of new genetic medicines to treat cardiometabolic diseases. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.

Regeneron Pharmaceuticals NASDAQ:REGN

$951.19 -8.22 (-0.86%)

Closing price 11/12/2026 04:00 PM Eastern

Extended Trading

$953.94 +2.75 (+0.29%)

As of 05:34 AM Eastern

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration with Mammoth Biosciences, Inc. to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.

Sanofi NASDAQ:SNY

$48.46 +0.03 (+0.06%)

Closing price 11/12/2026 04:00 PM Eastern

Extended Trading

$48.58 +0.12 (+0.25%)

As of 06:13 AM Eastern

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products. In addition, it offers poliomyelitis, pertussis, and hib pediatric vaccines; influenza, booster, meningitis, and travel and endemic vaccines, which includes hepatitis A, typhoid, cholera, yellow fever, and rabies vaccines. The company also provides cough, cold, and flu, allergy, and pain care products, as well as physical, mental, and digestive wellness products; and offers products for itching, hydration, aging, cracking, overnight, and specialty skincare needs like eczema. Further, it has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301, a treatment for alpha-synucleinopathies; Blackstone Life Sciences to develop pivotal studies and clinical development program; and Seagen Inc. to design, develop, and commercialize antibody-drug conjugates for cancer. Additionally, the company has a collaboration agreement with IGM Biosciences, Inc. to develop, manufacture, and commercialize IgM antibody; Skyhawk Therapeutics, Inc to discover and develop novel small molecules; and Adagene Inc., for the discovery and development of antibody-based therapies. It also has collaborations with Scribe Therapeutics Inc. to develop genome editing technologies; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest REGN, LLY, NVO, and SNY Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest REGN, LLY, NVO, and SNY Earnings

Compare Dividends

Latest REGN, LLY, NVO, and SNY Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

REGN, LLY, NVO, and SNY Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

REGN, LLY, NVO, and SNY Company Descriptions

Eli Lilly and Company NYSE:LLY

Novo Nordisk A/S NYSE:NVO

Regeneron Pharmaceuticals NASDAQ:REGN

Sanofi NASDAQ:SNY

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools